Using CER to Improve Antibiotic Prescribing and Outcomes in Children
Using CER to Improve Antibiotic Prescribing and Outcomes in Children
批准号:
8747637
负责人:
Adam L. Hersh
金额:
$16.02万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-01 至 2019-07-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The proposed career development award is designed to support the transition of Dr. Adam L. Hersh into an independent physician-scientist using comparative-effectiveness research (CER) methods applied to a patient- centered outcomes research (PCOR) agenda that is dedicated to improving the appropriateness, quality, and safety of antibiotic use of in pediatric care. Dr. Hersh is a pediatric infectious diseases specialist at he University of Utah. The next steps in his career development are to gain advanced skills in quality improvement, epidemiologic, and biostatistical methods for CER and health economics. Dr. Hersh has assembled a mentoring and advisory team with expertise that spans these areas. His AHRQ K08 application proposes 3 research and 4 career development aims that will collectively enable him to become a leader in the areas of antimicrobial stewardship and CER methods in pediatric infectious diseases. Dr. Hersh's application addresses the growing health and economic threat of antibiotic resistance, which is driven in part by the problem of antibiotic overuse. Two important areas of antibiotic overuse include (1) the use of broad-spectrum antibiotics instead of equally effective narrow- spectrum therapy, especially for respiratory infections such as pneumonia; and (2) the use of outpatient parenteral antibiotic therapy (OPAT) instead of equally effective, safer, and less costly oral therapy. The development and implementation of antimicrobial stewardship programs (ASPs) are key strategies to address antibiotic overuse in these areas. However, pediatric ASPs are limited by a weak evidence-base, particularly pertaining to their effectiveness in facilitating guideline uptake and in the comparative-effectiveness of OPAT versus oral therapy for common conditions such as pneumonia, both of which will be strengthened by the proposed research aims. Aim 1 will compare the use of guideline recommended narrow-spectrum antibiotic therapy for pneumonia between hospitals with and without ASPs in a large network of freestanding children's hospitals as a way to assess their effectiveness in facilitating guideline adoption. Aim 2 will compare clinical outcomes between oral therapy and OPAT for children with complicated pneumonia, a condition where treatment practices are highly variable. Finally, Aim 3 will compare the economic burden, including direct and indirect costs and caregiver quality-of-life, between children treated with oral therapy and OPAT in order to provide a better understanding of the economic and caregiver impact of OPAT. In addition to his research aims, Dr. Hersh has proposed four career development aims including coursework and practical experience in the areas of quality improvement; advanced epidemiologic and biostatistical methods for CER; health economics; and leadership. To complete these aims, Dr. Hersh will have access to strong, established resources. The Department of Pediatrics at the University of Utah and Primary Children's Hospital, operated by Intermountain Healthcare, provide ideal environments for the proposed award including a longstanding history and culture of collaborative scientific investigation in the areas of pediatric respiratory infections, quality improvement, implementation science, and CER. The Department of Pediatrics promotes success of early stage investigators by providing resources dedicated to enhancing access to mentorship and grant support services, including a Pediatric Clinical and Translational Research Scholars Program. The University of Utah has outstanding resources dedicated to mentorship, and early career development and training in biostatistical and epidemiologic methods for CER through the NIH-funded Center for Clinical and Translational Science (CCTS) and the Study Design and Biostatistics Center. Intermountain Healthcare offers the Advanced Training Program, a leading training program for physicians in the science of quality improvement. Dr. Hersh currently has 75% protected time which will be ensured throughout the award period to utilize these resources in achieving his career development goals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Using CER to Improve Antibiotic Prescribing and Outcomes in Children
-
批准号:9114045
-
项目类别:
-
资助金额:$16.02万
-
财政年份:2014
-
负责人:Adam L. Hersh
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Cer系统紊乱导致银屑病的分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:马杰
-
依托单位:
神经酰胺类似物 Cer-B1 通过 HDAC6/METTL3
调控 H3K27 乙酰化水平抗 AML 的机制研究
-
批准号:Q24H310019
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:王博林
-
依托单位:
CER(d18:1/18:1)调控LXRβ-RXRα异二聚体功能促进胆汁酸磺化解毒途径在改善胆汁淤积性肝损伤的关键作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:王恺
-
依托单位:
调控ASM/Cer通路改善脑卒中后缺血再灌注损伤的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:张晓旎
-
依托单位:
基于ADPN-Cer轴的柑橘黄酮调控能量负平衡奶牛脂肪组织脂解的分子机制
-
批准号:32302767
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:赵玉超
-
依托单位:
大麦叶鞘表皮蜡质β-二酮缺失突变体cer-b基因的图位克隆及功能分析
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:周琴
-
依托单位:
CER(d18:1/18:1)与NDUFA6相互作用抑制RC-I介导的反向电子传递ROS生成在改善肝缺血再灌注损伤的作用及机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:李川江
-
依托单位:
鞘脂通过Sa-Cer-GlcCer通路异常代谢参与HIV阴性患者肺隐球菌病的发病及其机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:叶枫
-
依托单位:
n-SMase2调控SM-Cer代谢通路对血压和血管功能的作用及机制研究
-
批准号:82000394
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:郭芊卉
-
依托单位:
CER2-LIKE1在大葱表皮超长链蜡质合成中的作用机制研究
-
批准号:31972409
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2019
-
负责人:王永勤
-
依托单位: